1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Cosmo Pharmaceuticals N.V.
  6. News
  7. Summary
    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
Delayed Swiss Exchange  -  11:30 2022-08-16 am EDT
53.70 CHF   +0.56%
07/28TRANSCRIPT : Cosmo Pharmaceuticals N.V., H1 2022 Earnings Call, Jul 28, 2022
CI
07/28Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/28Cosmo Pharmaceuticals Turns to Profit in H1 on New Products Boost
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cosmo Pharmaceuticals N : ' Shareholders approve all Agenda Items at Annual General Meeting

05/27/2022 | 10:21am EDT

Dublin, Ireland - 27 May 2022:Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced thatits shareholders approved all agenda items at today's virtual annual general meeting of shareholders.

8,315,019 ordinary shares in the share capital of Cosmo were represented at this virtual annual general meeting of shareholdersconstituting 47.40% of the total outstanding ordinary shares in the share capital of Cosmo (as of the record date).

  • The proposal to adopt the annual accounts of financial year 2021 ("FY 2021") was adopted with 99.96% of the votes represented.
  • The appropriation of the result of FY 2021 was adopted with 100% of the votes represented.
  • The proposal to approve the resolution of the Board of Directors to declare a distribution out of Cosmo's freely distributable reserves was adopted with 83.08% of the votes represented.
  • The proposal to grant discharge to the members of the Board of Directors in respect of their performed management, supervision and advice during FY 2021 was with 91.70% of the votes represented.
  • The proposal to amend the remuneration policy was adopted with 75.48% of the votes represented.
  • The proposal to grant options to subscribe for ordinary shares and/or rights to acquire ordinary shares to the Board of Directors with 75.48% of the votes represented.
  • Proposal to authorise the Board of Directors, for a period of eighteen (18) months after the date of this AGM or until the day of the next annual general meeting of shareholders of Cosmo (whichever comes first), to issue - and grant subscription rights to - ordinary shares up to a maximum nominal sum of ten percent (10%) and, in the event of a merger, an acquisition or a strategic alliance to increase this authorisation by a maximum of a further ten percent (10%) of the ordinary shares included in the authorised capital was adopted with 79.47% of the votes represented.
  • Proposal to authorise the Board of Directors, for a period of eighteen (18) months after the date of this AGM or until the day of the next annual general meeting of shareholders of Cosmo (whichever comes first), to issue - and grant subscription rights to - ordinary shares up to a maximum nominal sum of ten percent (10%) of the ordinary shares included in the authorised capital, which shares shall be issued for the execution of Cosmo's employee stock ownership plan for directors, employees, co-workers and administrators of Cosmo or a group company was adopted with 75.48% of the votes represented.
  • Proposal to authorise the Board of Directors, for a period of eighteen (18) months after the date of this AGM or until the day of the next annual general meeting of shareholders of Cosmo (whichever comes first), to issue preferred shares or to grant the right to subscribe for preferred shares up to the maximum number as provided for in Cosmo's articles of association with 75.17% of the votes represented.
  • Proposal to authorise the Board of Directors to acquire fully paid-up shares in the share capital of Cosmo up to a maximum of ten percent (10%) of the ordinary shares included in the authorised capital, for a period of eighteen (18) months after the date of this AGM or until the day of the next annual general meeting of shareholders of Cosmo (whichever comes first) was adopted with 82.44% of the votes represented.

About Cosmo Pharmaceuticals

Cosmo is a pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally including Lialda®, Uceris®/Cortiment® and Winlevi®. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ which uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Calendar

Half-Year 2022 Report July 28, 2022

Investora Conference, Zurich September 21-22, 2022

Credit Suisse Equity Forum Switzerland November 15-17, 2022

Jefferies 2022 London Healthcare Conference November 15-17, 2022

Contact

Hazel Winchester, Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com

Disclaimer
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

Disclaimer

Cosmo Pharmaceuticals NV published this content on 27 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 May 2022 14:20:08 UTC.


© Publicnow 2022
All news about COSMO PHARMACEUTICALS N.V.
07/28TRANSCRIPT : Cosmo Pharmaceuticals N.V., H1 2022 Earnings Call, Jul 28, 2022
CI
07/28Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended June 30, 20..
CI
07/28Cosmo Pharmaceuticals Turns to Profit in H1 on New Products Boost
MT
07/28Switzerland's Cosmo Pharmaceuticals Secures Licensing Deal for Acne Cream in China
MT
07/28Cosmo reports strong half-year 2022 financial results delivering record revenues and re..
EQ
07/28COSMO PHARMACEUTICALS N : Half-Year Results 2022 Webcast Presentation
PU
07/28Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
EQ
07/26Cosmo Unit Cassiopea Signs Acne Cream License, Supply Deal With India's Sun Pharmaceuti..
MT
07/26Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for ..
EQ
07/06Cosmo Pharmaceuticals N.V. - INVITATION TO COSMO'S HALF-YEAR 2022 RESULTS WEBCAST ON 28..
AQ
More news
Analyst Recommendations on COSMO PHARMACEUTICALS N.V.
More recommendations
Financials
Sales 2022 101 M 102 M 102 M
Net income 2022 27,5 M 28,0 M 28,0 M
Net cash 2022 41,6 M 42,4 M 42,4 M
P/E ratio 2022 34,7x
Yield 2022 0,87%
Capitalization 914 M 926 M 931 M
EV / Sales 2022 8,68x
EV / Sales 2023 6,20x
Nbr of Employees 292
Free-Float 48,0%
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 55,50 €
Average target price 89,17 €
Spread / Average Target 60,7%
EPS Revisions
Managers and Directors
Alessandro Della Chà Executive Director
Niall Donnelly Chief Financial Officer
Mauro Severino Ajani Director
Davide Malavasi Director-Qualified Person & Technical
Nhan Ngo Dinh Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
COSMO PHARMACEUTICALS N.V.-18.60%926
JOHNSON & JOHNSON-2.91%436 680
ELI LILLY AND COMPANY13.66%298 298
PFIZER, INC.-15.75%279 215
ROCHE HOLDING AG-16.14%277 502
ABBVIE INC.5.09%251 582